- Home
- RDIB vs TLSI Comparison
RDIB vs TLSI Comparison
Compare RDIB & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- TLSI
- Stock Information
- Founded
- RDIB 1937
- TLSI 2010
- Country
- RDIB United States
- TLSI United States
- Employees
- RDIB N/A
- TLSI N/A
- Industry
- RDIB Movies/Entertainment
- TLSI Medical Specialities
- Sector
- RDIB Consumer Discretionary
- TLSI Health Care
- Exchange
- RDIB Nasdaq
- TLSI Nasdaq
- Market Cap
- RDIB 259.2M
- TLSI 244.3M
- IPO Year
- RDIB N/A
- TLSI N/A
- Fundamental
- Price
- RDIB $10.97
- TLSI $4.08
- Analyst Decision
- RDIB
- TLSI Strong Buy
- Analyst Count
- RDIB 0
- TLSI 3
- Target Price
- RDIB N/A
- TLSI $10.67
- AVG Volume (30 Days)
- RDIB 4.0K
- TLSI 99.4K
- Earning Date
- RDIB 11-12-2025
- TLSI 11-13-2025
- Dividend Yield
- RDIB N/A
- TLSI N/A
- EPS Growth
- RDIB N/A
- TLSI N/A
- EPS
- RDIB N/A
- TLSI N/A
- Revenue
- RDIB $219,213,000.00
- TLSI $35,990,000.00
- Revenue This Year
- RDIB $6.85
- TLSI $57.25
- Revenue Next Year
- RDIB $10.86
- TLSI $54.05
- P/E Ratio
- RDIB N/A
- TLSI N/A
- Revenue Growth
- RDIB 7.59
- TLSI 45.50
- 52 Week Low
- RDIB $5.78
- TLSI $3.42
- 52 Week High
- RDIB $14.95
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- RDIB 44.30
- TLSI 29.36
- Support Level
- RDIB $11.23
- TLSI $4.25
- Resistance Level
- RDIB $12.21
- TLSI $4.80
- Average True Range (ATR)
- RDIB 0.33
- TLSI 0.22
- MACD
- RDIB -0.02
- TLSI -0.09
- Stochastic Oscillator
- RDIB 37.69
- TLSI 4.62
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.